Chronic myelogenous leukemia and exposure to ionizing radiation - a retrospective study of 443 patients

A. Corso, M. Lazzarino, E. Morra, S. Merante, C. Astori, P. Bernasconi, M. Boni, C. Bernasconi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Exposure to ionizing radiations (Rx) has been implicated as a causative factor of chronic myelogenous leukemia (CML). We performed a retrospective study of 443 consecutive CML patients, looking for a history of significant exposure to Rx, and evaluated the clinical and hematological characteristics in order to find any difference between radiation-related CML patients and those with de novo CML. We identified 406 patients without known exposure to mutagens (group I) and 37 patients with prior significant exposure to Rx (group II). In comparison to patients of group I, those of group II showed particular clinical and hematological features: significantly lower incidence of bulky splenomegaly (p100×109/l;p

Original languageEnglish
Pages (from-to)79-82
Number of pages4
JournalAnnals of Hematology
Volume70
Issue number2
DOIs
Publication statusPublished - Feb 1995

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ionizing Radiation
Retrospective Studies
Splenomegaly
Mutagens
Radiation
Incidence

Keywords

  • Chronic myeloid leukemia Radiotherapy
  • X-ray treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic myelogenous leukemia and exposure to ionizing radiation - a retrospective study of 443 patients. / Corso, A.; Lazzarino, M.; Morra, E.; Merante, S.; Astori, C.; Bernasconi, P.; Boni, M.; Bernasconi, C.

In: Annals of Hematology, Vol. 70, No. 2, 02.1995, p. 79-82.

Research output: Contribution to journalArticle

@article{a6053f79cbf14847903c8960c07e33c1,
title = "Chronic myelogenous leukemia and exposure to ionizing radiation - a retrospective study of 443 patients",
abstract = "Exposure to ionizing radiations (Rx) has been implicated as a causative factor of chronic myelogenous leukemia (CML). We performed a retrospective study of 443 consecutive CML patients, looking for a history of significant exposure to Rx, and evaluated the clinical and hematological characteristics in order to find any difference between radiation-related CML patients and those with de novo CML. We identified 406 patients without known exposure to mutagens (group I) and 37 patients with prior significant exposure to Rx (group II). In comparison to patients of group I, those of group II showed particular clinical and hematological features: significantly lower incidence of bulky splenomegaly (p100×109/l;p",
keywords = "Chronic myeloid leukemia Radiotherapy, X-ray treatment",
author = "A. Corso and M. Lazzarino and E. Morra and S. Merante and C. Astori and P. Bernasconi and M. Boni and C. Bernasconi",
year = "1995",
month = "2",
doi = "10.1007/BF01834384",
language = "English",
volume = "70",
pages = "79--82",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Chronic myelogenous leukemia and exposure to ionizing radiation - a retrospective study of 443 patients

AU - Corso, A.

AU - Lazzarino, M.

AU - Morra, E.

AU - Merante, S.

AU - Astori, C.

AU - Bernasconi, P.

AU - Boni, M.

AU - Bernasconi, C.

PY - 1995/2

Y1 - 1995/2

N2 - Exposure to ionizing radiations (Rx) has been implicated as a causative factor of chronic myelogenous leukemia (CML). We performed a retrospective study of 443 consecutive CML patients, looking for a history of significant exposure to Rx, and evaluated the clinical and hematological characteristics in order to find any difference between radiation-related CML patients and those with de novo CML. We identified 406 patients without known exposure to mutagens (group I) and 37 patients with prior significant exposure to Rx (group II). In comparison to patients of group I, those of group II showed particular clinical and hematological features: significantly lower incidence of bulky splenomegaly (p100×109/l;p

AB - Exposure to ionizing radiations (Rx) has been implicated as a causative factor of chronic myelogenous leukemia (CML). We performed a retrospective study of 443 consecutive CML patients, looking for a history of significant exposure to Rx, and evaluated the clinical and hematological characteristics in order to find any difference between radiation-related CML patients and those with de novo CML. We identified 406 patients without known exposure to mutagens (group I) and 37 patients with prior significant exposure to Rx (group II). In comparison to patients of group I, those of group II showed particular clinical and hematological features: significantly lower incidence of bulky splenomegaly (p100×109/l;p

KW - Chronic myeloid leukemia Radiotherapy

KW - X-ray treatment

UR - http://www.scopus.com/inward/record.url?scp=0028912258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028912258&partnerID=8YFLogxK

U2 - 10.1007/BF01834384

DO - 10.1007/BF01834384

M3 - Article

C2 - 7880928

AN - SCOPUS:0028912258

VL - 70

SP - 79

EP - 82

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 2

ER -